<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for Abbott Laboratories]]></title>
<description><![CDATA[Watch breaking news videos and read news updates about Abbott Laboratories on FOXBusiness.com.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=173906"/>
<item>
<title><![CDATA[Elan Rejects Latest Royalty Pharma Approach]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/23/elan-rejects-latest-royalty-pharma-approach/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/23/elan-rejects-latest-royalty-pharma-approach/</guid>
<pubDate><![CDATA[Thu, 23 May 2013 14:55:02 EDT]]></pubDate>
<description><![CDATA[Elan Corp. (ELN, DRX.DB) Thursday rejected the most recent approach by New York-based pharmaceutical investor Royalty Pharma AG, which values the company at around $6.4 billion.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Royalty Pharma Lowers Acceptance Threshold For Elan Offer]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/23/royalty-pharma-lowers-acceptance-threshold-for-elan-offer/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/23/royalty-pharma-lowers-acceptance-threshold-for-elan-offer/</guid>
<pubDate><![CDATA[Thu, 23 May 2013 08:17:09 EDT]]></pubDate>
<description><![CDATA[Royalty Pharma AG, the New York-based pharmaceutical investor bidding around $6.4 billion in cash for drugmaker Elan Corp. (ELN) Thursday said it was lowering the threshold for shareholder acceptance for its offer to 50% plus one share, from an earlier 90%.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Royalty Pharma Raises Takeover Bid for Elan]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/20/royalty-pharma-raises-takeover-bid-for-elan/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/20/royalty-pharma-raises-takeover-bid-for-elan/</guid>
<pubDate><![CDATA[Mon, 20 May 2013 15:15:02 EDT]]></pubDate>
<description><![CDATA[U.S. pharmaceutical investor Royalty Pharma on Monday raised its multibillion-dollar takeover bid for Dublin-based Elan Corp. (DRX.DB, ELN) by 11% to $12.50 a share in cash, adding pressure on Elan as it moves to rebuild its business and secure its independence.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Abbott Laboratories Lifted To Buy At Goldman Sachs]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2013/05/20/abbott-laboratories-lifted-to-buy-at-goldman-sachs/?]]></link>
<guid>http://www.foxbusiness.com/markets/2013/05/20/abbott-laboratories-lifted-to-buy-at-goldman-sachs/</guid>
<pubDate><![CDATA[Mon, 20 May 2013 04:03:00 EDT]]></pubDate>
<description><![CDATA[Abbott Laboratories was upgraded to buy from neutral by Goldman Sachs, which also lifted its 12-month price target to $44 from $38 per share.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[AbbVie, Alvine Pharma to Collaborate on Investigational Drug for Celiac Disease]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/14/abbvie-alvine-pharma-to-collaborate-on-investigational-drug-for-celiac-disease/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/14/abbvie-alvine-pharma-to-collaborate-on-investigational-drug-for-celiac-disease/</guid>
<pubDate><![CDATA[Tue, 14 May 2013 10:06:04 EDT]]></pubDate>
<description><![CDATA[AbbVie Inc. (ABBV) will pay at least $70 million in a collaboration deal with privately held Alvine Pharmaceuticals to develop an oral treatment for celiac disease.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[AbbVie Chief Scientific Officer John Leonard to Retire]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/10/abbvie-chief-scientific-officer-john-leonard-to-retire/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/10/abbvie-chief-scientific-officer-john-leonard-to-retire/</guid>
<pubDate><![CDATA[Fri, 10 May 2013 17:05:26 EDT]]></pubDate>
<description><![CDATA[AbbVie Inc. (ABBV), the pharmaceutical business spun off from Abbott Laboratories (ABT), said its head of research and development will retire from the company.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[S&P Highlights Biotech ETFs]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/10/sp-highlights-biotech-etfs/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/10/sp-highlights-biotech-etfs/</guid>
<pubDate><![CDATA[Fri, 10 May 2013 03:39:47 EDT]]></pubDate>
<description><![CDATA[Bolstered by an accommodating Food & Drug Administration and promising recent clinical results for drugs aimed at treating conditions such as hepatitis C and multiple sclerosis, biotechnology stocks and ETFs have been stellar performers in 2013.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[BOND REPORT: Apple Prices $17 Bln Bond Deal To Strong Demand]]></title>
<link><![CDATA[http://www.foxbusiness.com/technology/2013/04/30/bond-report-apple-prices-17-bln-bond-deal-to-strong-demand/?]]></link>
<guid>http://www.foxbusiness.com/technology/2013/04/30/bond-report-apple-prices-17-bln-bond-deal-to-strong-demand/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 17:28:27 EDT]]></pubDate>
<description><![CDATA[Apple Inc. priced a supersized $17 billion corporate bond deal Tuesday, the largest ever for a nonfinancial U.S. corporate issuer.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Apple wows market with record $17billion bond deal]]></title>
<link><![CDATA[http://www.foxbusiness.com/technology/2013/04/30/apple-wows-market-with-record-17billion-bond-deal/?]]></link>
<guid>http://www.foxbusiness.com/technology/2013/04/30/apple-wows-market-with-record-17billion-bond-deal/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 15:03:08 EDT]]></pubDate>
<description><![CDATA[NEW YORK/LONDON, April 30 (IFR) - Apple Inc wowed the debt markets on Tuesday with the largest non-bank bond deal in history, offering a whopping $17 billion for sale as the U.S. computer giant switches strategy to placate restless shareholders.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/04/30/2013-04-30T190308Z_1_CBRE93T1GXP00_3_USA-RETAIL-HOLIDAY-THANKSGIVING.JPG</media:thumbnail>
</item>
<item>
<title><![CDATA[BOND REPORT: Apple Launches $17 Bln Bond Deal]]></title>
<link><![CDATA[http://www.foxbusiness.com/technology/2013/04/30/bond-report-apple-launches-17-bln-bond-deal/?]]></link>
<guid>http://www.foxbusiness.com/technology/2013/04/30/bond-report-apple-launches-17-bln-bond-deal/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 14:23:52 EDT]]></pubDate>
<description><![CDATA[Apple Inc. launched a supersized $17 billion corporate bond deal Tuesday, according to Tom Tucci, managing director and head of Treasury trading at CIBC World Markets Corp.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[BOND REPORT: Apple Sees High Demand For Bond Offering]]></title>
<link><![CDATA[http://www.foxbusiness.com/technology/2013/04/30/bond-report-apple-sees-high-demand-for-bond-offering/?]]></link>
<guid>http://www.foxbusiness.com/technology/2013/04/30/bond-report-apple-sees-high-demand-for-bond-offering/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 13:31:38 EDT]]></pubDate>
<description><![CDATA[The corporate bond market was eagerly awaiting an offering Tuesday from Apple Inc., one of the largest deals in recent memory.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Auction of Brazilian Drug Company Ache Stalls on Differences Among Family Owners -Sources]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/30/auction-brazilian-drug-company-ache-stalls-on-differences-among-family-owners/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/30/auction-brazilian-drug-company-ache-stalls-on-differences-among-family-owners/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 11:43:42 EDT]]></pubDate>
<description><![CDATA[The auction of Ach� Laborat�rios Farmac�uticos SA, which has drawn interest from some of the biggest names in the global healthcare industry, has stalled due to disagreement among the Brazilian drug company's family owners, according to people familiar with the matter.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Verizon seen having clear path to funds for Vodafone deal]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/29/verizon-seen-having-clear-path-to-funds-for-vodafone-deal/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/29/verizon-seen-having-clear-path-to-funds-for-vodafone-deal/</guid>
<pubDate><![CDATA[Mon, 29 Apr 2013 04:45:05 EDT]]></pubDate>
<description><![CDATA[LONDON/NEW YORK, April 25 - Verizon would likely have little trouble rustling up $50 billion or more in the debt markets to help fund the full buyout of Verizon Wireless from UK partner Vodafone, bankers and analysts said on Thursday.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/04/29/2013-04-29T084505Z_1_CBRE93S0E2F00_3_USA.JPG</media:thumbnail>
</item>
<item>
<title><![CDATA[AbbVie 1st-Quarter Profit Rises 9.6% on Strong Sales of Humira]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/26/abbvie-1st-quarter-profit-rises-6-on-strong-sales-humira/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/26/abbvie-1st-quarter-profit-rises-6-on-strong-sales-humira/</guid>
<pubDate><![CDATA[Fri, 26 Apr 2013 09:42:29 EDT]]></pubDate>
<description><![CDATA[AbbVie Inc. (ABBV) reported a 9.6% rise in profit for its first quarter as an independent company, helped by continued strong sales growth for arthritis drug Humira.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[AbbVie Profit Rises, Boosted by Humira Sales]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/26/abbvie-profit-rises-boosted-by-humira-sales/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/26/abbvie-profit-rises-boosted-by-humira-sales/</guid>
<pubDate><![CDATA[Fri, 26 Apr 2013 08:35:06 EDT]]></pubDate>
<description><![CDATA[AbbVie Inc.'s (ABBV) first-quarter earnings rose 9.6% as a double-digit-percentage rise in sales of Humira helped to improve margins.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Health-Care Companies Report Slowdown in Patient Visits]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/23/health-care-companies-report-slowdown-in-patient-visits/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/23/health-care-companies-report-slowdown-in-patient-visits/</guid>
<pubDate><![CDATA[Tue, 23 Apr 2013 09:46:39 EDT]]></pubDate>
<description><![CDATA[The spike late last year in doctor and hospital visits apparently lasted as long as the flu.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Analysis: Ahead of reform, medical care slowdown hits companies]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/22/analysis-ahead-reform-medical-care-slowdown-hits-companies/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/22/analysis-ahead-reform-medical-care-slowdown-hits-companies/</guid>
<pubDate><![CDATA[Mon, 22 Apr 2013 01:11:00 EDT]]></pubDate>
<description><![CDATA[As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fewer trips to the doctor's office.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/04/22/2013-04-22T051100Z_2_CBRE93L0EBI00_3_USA-CAMPAIGN.JPG</media:thumbnail>
</item>
<item>
<title><![CDATA[S&P Likes The Biggest Dividend ETF]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/19/sp-likes-biggest-dividend-etf/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/19/sp-likes-biggest-dividend-etf/</guid>
<pubDate><![CDATA[Fri, 19 Apr 2013 08:39:47 EDT]]></pubDate>
<description><![CDATA[Dividend stocks and ETFs have been all the rage this year, underscoring the risk off nature of the broader market's rally.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA['New Abbott' Labs Sees Sales Boost From Emerging Markets]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/17/new-abbott-labs-sees-sales-boost-from-emerging-markets/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/17/new-abbott-labs-sees-sales-boost-from-emerging-markets/</guid>
<pubDate><![CDATA[Wed, 17 Apr 2013 12:35:08 EDT]]></pubDate>
<description><![CDATA[Abbott Laboratories' (ABT) first-quarter revenues rose 1.8% as sales of baby formula and other nutritional products in emerging markets helped offset declines in the U.S. and Europe, where austerity measures and tough economic conditions continued to pressure use of its medical devices.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Abbott 1st-Quarter Profit Fell 56% On Spinoff; Remaining Operations See Growth]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/17/abbott-1st-quarter-profit-fell-56-on-spinoff-remaining-operations-see-growth/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/17/abbott-1st-quarter-profit-fell-56-on-spinoff-remaining-operations-see-growth/</guid>
<pubDate><![CDATA[Wed, 17 Apr 2013 08:27:37 EDT]]></pubDate>
<description><![CDATA[Abbott Laboratories' (ABT) first-quarter earnings fell 56% as the year-earlier period included contributions from its former research-based pharmaceutical business, while performance at its remaining operations improved.]]></description>
<media:thumbnail/>
</item>
</channel>
</rss>
